Barclays PLC Axsome Therapeutics, Inc. Call Options Transaction History

Barclays PLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	SELL	$69.39 - $97.64 $1.7 Million - $2.39 Million	-24,500 Reduced 47.12%	27,500 $2.2 Million
Q4 2023 Feb 15, 2024	BUY	$57.42 - $83.61 $2.99 Million - $4.35 Million	52,000 New	52,000 $4.14 Million
Q1 2020 May 13, 2020	BUY	$41.2 - $101.31 $5.63 Million - $13.8 Million	136,600 Added 210.48%	201,500 $11.9 Million
Q4 2019 Feb 10, 2020	BUY	$16.71 - $106.24 $751,950 - $4.78 Million	45,000 Added 226.13%	64,900 $6.71 Million
Q3 2019 Nov 14, 2019	SELL	$20.24 - $29.16 $797,455 - $1.15 Million	-39,400 Reduced 66.44%	19,900 $403,000

Q2 2019 Aug 14, 2019	SELL	$13.46 - $25.75 $508,788 - $973,350	-37,800 Reduced 38.93%	59,300 $1.53 Million
Q1 2019 May 15, 2019	BUY	$2.63 - $16.34 $255,373 - $1.59 Million	97,100 New	97,100 $1.38 Million

290

37.1M

401K

464K

Ticker AXSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,878,000
Market Cap $3.44B
Description
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.